Prime Medicine - About the company
Prime Medicine is a public company based in Cambridge (United States), founded in 2019 by Mobeen Gajee. It operates as a Developer of genetic therapies for a wide range of diseases. Prime Medicine has raised $315M in funding. The company has 122 active competitors, including 60 funded and 12 that have exited. Its top competitors include companies like Beam Therapeutics, eGenesis and Mammoth.
Company Details
Developer of genetic therapies for a wide range of diseases. The company uses next-generation gene editing and prime editing technology to develop genetic therapies to address the widest spectrum of diseases.
- Website
- primemedicine.com
- Email ID
- *****@primemedicine.com
- Registered Address
- 21 Erie Street Cambridge, MA 02139
Key Metrics
Founded Year
2019
Location
Cambridge, United States
Stage
Public
Total Funding
$315M in 2 rounds
Latest Funding Round
Investors
Ranked
7th among 122 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2025
Employee Count
187 as on Jun 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Prime Medicine
Prime Medicine is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Prime Medicine, Inc CIN: 84-3097762 , United States, Active | Sep 12, 2019 | - | 214 (As on Dec 31, 2024) | - |
PRIME MEDICINE, INC. CIN: 1894562 , United States, Active | Sep 12, 2019 | $1M - $10M (As on Dec 31, 2025) | 171 (As on Dec 31, 2022) | - |
Prime Medicine's IPO details
Prime Medicine got listed on Oct 20, 2022.
Click here to take a look at Prime Medicine's IPO in detail
Sign up to download Prime Medicine's company profile
Prime Medicine's funding and investors
Prime Medicine has raised a total funding of $315M over 2 rounds. Its latest funding round was a Series B round on Jul 13, 2021 for $*****. 10 investors participated in its latest round. Prime Medicine has 12 institutional investors.
Here is the list of recent funding rounds of Prime Medicine:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 13, 2021 | 1611939 | Series B | 9647300 | 9244426 | 5977357 | 2249796 |
Access funding benchmarks and valuations. Sign up today!View details of Prime Medicine's funding rounds and investors
Prime Medicine's founders and board of directors
Founder? Claim ProfileThe founders of Prime Medicine is Mobeen Gajee.
Here are the details of Prime Medicine's key team members:
- Mobeen Gajee: Founder of Prime Medicine.
View details of Prime Medicine's Founder profiles and Board Members
Prime Medicine's employee count trend
Prime Medicine has 187 employees as of Jun 26. Here is Prime Medicine's employee count trend over the years:
Uncover Prime Medicine's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Prime Medicine's Competitors and alternates
Top competitors of Prime Medicine include Beam Therapeutics, eGenesis and Mammoth. Here is the list of Top 10 competitors of Prime Medicine, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 71/100 | |
2nd | eGenesis 2015, Cambridge (United States), Series D | Developer of a gene transplantation platform for humanizing pig cells | $481M | 65/100 | |
3rd |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
4th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 64/100 | |
5th | Tessera Therapeutics 2017, Cambridge (United States), Series C | Provider of new genome engineering technology for treating multiple diseases | $610M | 64/100 | |
6th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
7th |  Prime Medicine 2019, Cambridge (United States), Public | Developer of genetic therapies for a wide range of diseases | $315M | 64/100 | |
8th |  Scribe Therapeutics 2018, Alameda (United States), Series B | Developer of a gene-editing platform using CRISPR technology | $120M | 62/100 | |
9th | _1558958387529.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kytopen 2017, Cambridge (United States), Series B | Developer of gene delivery systems for cell therapy | $44.5M | 61/100 | |
10th | _1576054856947.png?devicePixelRatio=2&height=30&width=30){kind=logo} Watchmaker Genomics 2018, Boulder (United States), Series A | Developer of gene-editing technology | $48.3M | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Prime Medicine's competitors? Click here to see the top ones
Prime Medicine's Investments and acquisitions
Prime Medicine has made no investments or acquisitions yet.
Reports related to Prime Medicine
Here is the latest report on Prime Medicine's sector:
News related to Prime Medicine
Filter this listMedia has covered Prime Medicine for a total of 18 events in the last 1 year, 8 of them have been about company updates and 1 about people movement.
•
Prime Medicine Reports Q2 2026 Financial Results and Business UpdatesGlobeNewswire•Aug 06, 2026•Prime Medicine
•
•
•
•
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire•May 07, 2026•Prime Medicine
•
•
•
Prime Medicine to Seek FDA Approval of Previously Shelved Gene TherapyEndpoints•Mar 04, 2026•Prime Medicine
•
•
Prime Medicine, Inc. $PRME Shares Acquired by Alphabet Inc.MarketBeat•Feb 14, 2026•Prime Medicine, Alphabet
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Prime Medicine
Explore our recently published companies
- Saalfo Tech - Mysuru based, 1990 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - India based, Unfunded company
- Diamondexch99 - Unfunded company
- Krishna's Herbal & Ayurveda - Jodhpur based, 2007 founded, Funding Raised company
- Dash - Atlanta based, 2025 founded, Unfunded company
